Editas Medicine, Inc.

Some of the best links we picked up around the internet

CMN Weekly (8 November 2024) - Your Weekly CRISPR...

CMN Weekly

Nov. 8, 2024

Some of the best links we picked up around the internet

CMN Weekly (25 October 2024) - Your Weekly CRISPR...

CMN Weekly

Oct. 25, 2024

Some of the best links we picked up around the internet

CMN Weekly (11 October 2024) - Your Weekly CRISPR...

CMN Weekly

Oct. 11, 2024

Some of the best links we picked up around the internet

CMN Weekly (4 October 2024) - Your Weekly CRISPR...

CMN Weekly

Oct. 4, 2024

Some of the best links we picked up around the internet

CMN Weekly (9 August 2024) - Your Weekly CRISPR...

CMN Weekly

Aug. 9, 2024

Some of the best links we picked up around the internet

The Latest Updates From the Gene-Editing Clinical...

CMN Clinical

Jul. 17, 2024

In this clinical update, we bring you the latest news from four gene-editing trials sponsored by Beam Therapeutics, Intellia Therapeutics, Editas...

Gene-Editing Highlights from Retina International...

Jun. 26, 2024

Earlier this month, CRISPR Medicine News attended Retina International World Congress 2024 in Dublin. Gene-editing advances presented at the...

Editas Medicine, Inc.

Retinal Degeneration, (NCT03396042)
Sponsors:
Editas Medicine, Inc.

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, and Transfusion Dependent Beta-Thalassemia, TDT, (NCT06363760)
Sponsors:
Editas Medicine, Inc.

IND Enabling

Phase I

Phase II

Phase III

Transfusion-Dependent Beta-Thalassemia, TDT, (NCT05444894)
Sponsors:
Editas Medicine

IND Enabling

Phase I

Phase II

Phase III

Sickle Cell Disease, SCD, (NCT04853576)
Sponsors:
Editas Medicine, Inc.

IND Enabling

Phase I

Phase II

Phase III

Leber Congenital Amaurosis, LCA, (NCT03872479)
Sponsors:
Editas Medicine, Inc.

IND Enabling

Phase I

Phase II

Phase III